92 Results for "

ATM

" in MedChemExpress (MCE) Product Catalog:
Products (92)

92 Results for "ATM" in MCE Product Catalog:

  • Isoforms Recommended:
  • Targets Recommended:
  • Recombinant Proteins Recommended:
66
66 Publications Verification
Cat. No.: HY-12016
CAS No.: 587871-26-9
Purity:  99.92%
Target:  

ATM/ATR Autophagy

Research Areas:  

Cancer

KU-55933 is a potent ATM inhibitor with an IC50 and Ki of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
28
28 Cited Publications
Cat. No.: HY-12061
CAS No.: 925701-46-8
Purity:  99.43%
Target:  

ATM/ATR

Research Areas:  

Cancer

KU-60019 is an improved ATM kinase-specific inhibitor with IC50 of 6.3 nM.
16
16 Cited Publications
Cat. No.: HY-B0097
CAS No.: 50-91-9
Synonyms: 5-Fluorouracil 2'-deoxyriboside
Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .
16
16 Cited Publications
Cat. No.: HY-100016
CAS No.: 1821428-35-6
Purity:  99.83%
Target:  

ATM/ATR Apoptosis

Research Areas:  

Cancer

AZD0156 is a potent, selective and orally active ATM inhibitor with an IC50 of 0.58 nM. AZD0156 inhibits the ATM-mediated signaling, prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis .
10
10 Cited Publications
Cat. No.: HY-109566
CAS No.: 2089288-03-7
Purity:  99.22%
Target:  

ATM/ATR

Research Areas:  

Inflammation/Immunology Cancer

AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC50 of 0.78 nM in cell .
9
9 Cited Publications
Cat. No.: HY-19959
CAS No.: 1198097-97-0
Target:  

ATM/ATR Apoptosis

Research Areas:  

Cancer

Mirin is a potent Mre11-Rad50-Nbs1 (MRN) complex inhibitor. Mirin prevents MRN-dependent activation of ATM (IC50=12 μM) without affecting ATM protein kinase activity, and it inhibits Mre11-associated exonuclease activity. Mirin abolishes the G2/M checkpoint and homology-dependent repair in mammalian cells. Mirin prevents ATM activation in response to DNA double-strand breaks (DSBs) and blocks homology-directed repair (HDR) in mammalian cells .
9
9 Cited Publications
Cat. No.: HY-117693
CAS No.: 299953-00-7
Purity:  98.62%
Target:  

ATM/ATR

Research Areas:  

Cancer

(E/Z)-Mirin is a mixture of (E)-Mirin and Mirin ((Z)-Mirin) (HY-19959) configurations. Among them, Mirin is an inhibitor of MRN (Mre11-Rad50-Nbs1). Mirin prevents MRN-dependent ATM activation without affecting ATM protein kinase activity .
8
8 Cited Publications
Cat. No.: HY-123834
CAS No.: 824983-91-7
Purity:  99.85%
Target:  

FLAP ATM/ATR

Research Areas:  

Cancer

FEN1-IN-1 (compound 1) is a small molecule flap endonuclease 1 (FEN1) inhibitor with antitumor activity. FEN1-IN-1 binds to the active site of FEN1 and partly achieves inhibition by the co-ordination of Mg 2+ ions. FEN1-IN-1 initiaties a DNA damage response and activates the ATM checkpoint signalling pathway, the phosphorylation of histone H2AX and the ubiquitination of FANCD2 in mammalian cells. FEN1-IN-1 is promising for research of cancers .
7
7 Cited Publications
Cat. No.: HY-15520
CAS No.: 905973-89-9
Purity:  99.83%
Target:  

ATM/ATR

Research Areas:  

Cancer

CGK733 is a potent ATM/ATR inhibitor, used for the research of cancer.
5
5 Cited Publications
Cat. No.: HY-16705
CAS No.: 1374601-40-7
Research Areas:  

Cancer

BRD4770 is a histone methyltransferase G9a inhibitor. BRD4770 reduces di- and trimethylation of lysine 9 on histone H3 (H3K9) with an EC50 of 5 μM, and has less or little effect toward H3K27me3, H3K36me3, H3K4me3, and H3K79me3. BRD4770 can activate the ataxia telangiectasia mutated (ATM) pathway and induce cell senescence .
4
4 Cited Publications
Cat. No.: HY-15290
CAS No.: 873305-35-2
Purity:  99.95%
Target:  

Ack1

Research Areas:  

Cancer

AIM-100 is a potent and selective Ack1 inhibitor with an IC50 of 21.58 nM. AIM-100 also inhibits Tyr 267 phosphorylation. AIM-100 does not inhibits other kinases including PI3-kinase and AKT subfamily members. AIM-100 has an anticancer effect .
4
4 Cited Publications
Cat. No.: HY-11002
CAS No.: 1080622-86-1
Purity:  99.74%
Target:  

ATM/ATR

Research Areas:  

Cancer

CP-466722 is a rapidly reversible inhibitor of ATM, with an IC50 of 0.41 μM, and has no effects on PI3K or closely related PI3K-like protein kinase (PIKK) family members.
3
3 Cited Publications
Cat. No.: HY-139609
CAS No.: 2417489-10-0
Purity:  99.75%
Synonyms: RP-3500; ATR inhibitor 4
Target:  

ATM/ATR mTOR

Research Areas:  

Cancer

Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .
3
3 Cited Publications
Cat. No.: HY-103241
CAS No.: 293762-45-5
Purity:  99.10%
Ro 90-7501 is an amyloid β42 (Aβ42) fibril assembly inhibitor that reduces 42-induced cytotoxicity (EC50 of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response . Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .
2
2 Cited Publications
Cat. No.: HY-150617
CAS No.: 2495096-26-7
Purity:  99.94%
Synonyms: M4076; ATM Inhibitor-5
Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase ATM with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity .
1
1 Cited Publications
Cat. No.: HY-18650
CAS No.: 845932-30-1
Target:  

ATM/ATR

Research Areas:  

Cancer

KU 59403 is a potent ATM inhibitor, with IC50 values of 3 nM, 9.1 μM and 10 μM for ATM, DNA-PK and PI3K, respectively .
1
1 Cited Publications
Cat. No.: HY-136835
CAS No.: 1216676-34-4
Purity:  99.74%
Target:  

ATM/ATR

Research Areas:  

Neurological Disease

GJ071 oxalate induces ATM kinase activity in ataxia telangiectasia (A-T) cells carrying homozygous TGA or TAG stop codons .
Cat. No.: HY-157941
CAS No.: 2267316-76-5
Purity:  99.89%
Research Areas:  

Cancer

ART0380 is a potent, selective and orally active ATR kinase inhibitor. ART0380 potently inhibits human ATR-ATRIP complex with an IC50 of 51.7 nM. ART0380 binds the ATP pocket of the ATR-ATRIP complex, blocks ATR-dependent Chk1 serine 345 phosphorylation, and induces cell cycle disorder and DNA damage. ART0380 demonstrates potent and selective antitumor activity in preclinical models with varying types of ataxia-telangiectasia mutated (ATM) gene aberrancy. ART0380 can be used for the research of cancer, such as colorectal cancer and prostate cancer .
Cat. No.: HY-162472
CAS No.: 2595308-10-2
Target:  

ATM/ATR DNA-PK

Research Areas:  

Cancer

XRD-0394 is a potent and orally active dual ATM and DNA-PKcs inhibitor with IC50s of 0.39 nM and 0.89 nM, respectively. XRD-0394 shows selectivity over other PIKK and PI3K family members. XRD-0394 significantly enhances tumor cell killing in vitro and in vivo under therapeutic ionizing radiation conditions. XRD-0394 can potentiate the effects of PARP and topoisomerase I inhibitors in vitro .
Cat. No.: HY-171124
Synonyms: AZD9592
Tilatamig samrotecan (AZD9592) is an anti-EGFR/c-MET antibody-drug conjugate (ADC). Tilatamig samrotecan consists of an anti-EGFR/c-MET antibody with the drug-linker conjugate being AZ14170133 (HY-145399) (a topoisomerase I (TOP1i) inhibitor payload). Tilatamig samrotecan induces multiple DNA damage response pathway markers (like ATM, ATR, γH2AX). Tilatamig samrotecan selectively binds to EGFR and c-MET, delivering the cytotoxic payload. Tilatamig samrotecan exerts anti-tumor activity in vivo. Tilatamig samrotecan can be used for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) research .